Jefferies & Co Upgrades Biogen Idec (BIIB) to Buy
BIIB Hot Sheet
Rating Summary:15 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 24 | Down: 13 | New: 29
Jefferies & Co upgrades Biogen Idec (Nasdaq: BIIB) from Hold to Buy. Price target $50.
To see more analyst ratings on BIIB Click Here.
Biogen Idec Inc., a biotechnology company, develops, manufactures, and commercializes novel therapeutics in the areas of oncology, neurology, immunology, and cardiology in the United States and internationally.
To see more analyst ratings on BIIB Click Here.
Biogen Idec Inc., a biotechnology company, develops, manufactures, and commercializes novel therapeutics in the areas of oncology, neurology, immunology, and cardiology in the United States and internationally.
You May Also Be Interested In
- UPDATE: Nomura Securities Upgrades ASML Inc. (ASML) to Buy; Revenue Outlook Underestimated
- RBCC, Amarantus Move Forward with Joint Venture Discussions
- New Analysis of Risk Stratification for TYSABRI® Published in New England Journal of Medicine
Create E-mail Alert Related Categories
UpgradesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
